Kerstin Trunzer

3.3k total citations
16 papers, 556 citations indexed

About

Kerstin Trunzer is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Kerstin Trunzer has authored 16 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Genetics. Recurrent topics in Kerstin Trunzer's work include Melanoma and MAPK Pathways (4 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Kerstin Trunzer is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Kerstin Trunzer collaborates with scholars based in Switzerland, United States and Spain. Kerstin Trunzer's co-authors include Julien Mazières, Federico Cappuzzo, Nadja Triller, Raimundas Sakalauskas, Wolfram Brugger, Carol Ward, Maria Błasińska-Morawiec, Georgy M. Manikhas, Renaud Whittom and Olivia Spleiss and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Kerstin Trunzer

16 papers receiving 546 citations

Peers

Kerstin Trunzer
Patricia Tresca France
L. Véronèse Switzerland
Eleanor Gutteridge United Kingdom
Muaiad Kittaneh United States
Bogusława Karaszewska Poland
Reshma Mahtani United States
C. Hudis United States
Xueqian Gong United States
S. Johnston United Kingdom
Riccardo Ricotta Italy
Patricia Tresca France
Kerstin Trunzer
Citations per year, relative to Kerstin Trunzer Kerstin Trunzer (= 1×) peers Patricia Tresca

Countries citing papers authored by Kerstin Trunzer

Since Specialization
Citations

This map shows the geographic impact of Kerstin Trunzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerstin Trunzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerstin Trunzer more than expected).

Fields of papers citing papers by Kerstin Trunzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerstin Trunzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerstin Trunzer. The network helps show where Kerstin Trunzer may publish in the future.

Co-authorship network of co-authors of Kerstin Trunzer

This figure shows the co-authorship network connecting the top 25 collaborators of Kerstin Trunzer. A scholar is included among the top collaborators of Kerstin Trunzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerstin Trunzer. Kerstin Trunzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Sirinukunwattana, Korsuk, Jens Rittscher, Olga K. Weinberg, et al.. (2024). Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa. HemaSphere. 8(6). e105–e105. 1 indexed citations
3.
Verstovšek, Srđan, Lynda Foltz, Vikas Gupta, et al.. (2023). Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica. 108(10). 2730–2742. 13 indexed citations
4.
Sirinukunwattana, Korsuk, Jens Rittscher, Olga K. Weinberg, et al.. (2023). Quantitative Analysis of Bone Marrow Features Highlights Heterogeneity in Myelofibrosis Patients Treated with Zinpentraxin Alfa in a Phase II Clinical Study. Blood. 142(Supplement 1). 4558–4558. 2 indexed citations
5.
6.
Ardizzoni, Andrea, Sérgio Jobim Azevedo, Belén Rubio‐Viqueira, et al.. (2021). Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 9(3). e001865–e001865. 34 indexed citations
7.
Bubendorf, Lukas, Esther Conde, Federico Cappuzzo, et al.. (2020). A noninterventional, multinational study to assess PD‐L1 expression in cytological and histological lung cancer specimens. Cancer Cytopathology. 128(12). 928–938. 14 indexed citations
8.
Wolf, Jennifer Moriatis, Åslaug Helland, In‐Jae Oh, et al.. (2019). OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses. Journal of Thoracic Oncology. 14(10). S210–S210. 6 indexed citations
9.
Bosch, Francesc, Guy Cantin, Agostino Cortelezzi, et al.. (2019). Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 34(2). 441–450. 6 indexed citations
10.
Bubendorf, Lukas, et al.. (2017). Abstract 655: Development of IHC staining protocols for assessment of PD-L1 expression in cytological samples. Cancer Research. 77(13_Supplement). 655–655. 3 indexed citations
11.
Zelenetz, Andrew D., Mehrdad Mobasher, Luciano J. Costa, et al.. (2013). Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g). Blood. 122(21). 1820–1820. 16 indexed citations
12.
Lacouture, Mario E., Madeleine Duvic, Axel Hauschild, et al.. (2013). Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma. The Oncologist. 18(3). 314–322. 156 indexed citations
13.
Sosman, Jeffrey A., Anna C. Pavlick, Lynn M. Schuchter, et al.. (2012). Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.. Journal of Clinical Oncology. 30(15_suppl). 8503–8503. 19 indexed citations
14.
McArthur, Grant A., Antoni Ribas, Paul B. Chapman, et al.. (2011). Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts).. Journal of Clinical Oncology. 29(15_suppl). 8502–8502. 28 indexed citations
15.
Lacouture, Mario E., Paul B. Chapman, Antoni Ribas, et al.. (2011). Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.. Journal of Clinical Oncology. 29(15_suppl). 8520–8520. 15 indexed citations
16.
Brugger, Wolfram, Nadja Triller, Maria Błasińska-Morawiec, et al.. (2011). Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(31). 4113–4120. 217 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patricia Tresca Breakdown of academic impact, for papers by L. Véronèse Breakdown of academic impact, for papers by Eleanor Gutteridge Breakdown of academic impact, for papers by Muaiad Kittaneh Breakdown of academic impact, for papers by Bogusława Karaszewska Breakdown of academic impact, for papers by Reshma Mahtani Breakdown of academic impact, for papers by C. Hudis Breakdown of academic impact, for papers by Xueqian Gong Breakdown of academic impact, for papers by S. Johnston Breakdown of academic impact, for papers by Riccardo Ricotta
Rankless by CCL
2026